Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia

Mohammed T Tayeb, Caroline Clark, Neva Elizabeth Haites, Linda Sharp, Graeme Ian Murray, Howeard L. McLeod

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

OBJECTIVE: Prostate cancer (PRCa) is one of the most common causes of cancer death in men and determinants of PRCa risk remain largely unidentified. Benign prostatic hyperplasia (BPH) is found in the majority of ageing men and has been associated with PRCa. Many candidate genes have been suggested to be involved in PRCa, such as those that are central to cellular growth and differentiation in the prostate gland. The vitamin D receptor (VDR) and HER-2 protooncogene have been shown to be involved in the regulation of cell proliferation and differentiation in prostate cells. Genetic variations of these genes could be useful to detect BPH patients that have a higher risk of developing PRCa. This study used a case-control design to assess the predictive value of 3 polymorphisms in VDR (TaqI and FokI) and HER-2 (Val655Ile) to determine the risk of developing PRCa in patients with BPH. METHODS: Polymorphisms were detected by RFLP analysis. The study evaluated 28 patients who presented with PRCa at least 6 years after the diagnosis of BPH and 56 matched patients with BPH who did not progress to PRCa over a comparable period. The study was carried out in University of Aberdeen, Foresterhill, Aberdeen, United Kingdom in the year 2002. RESULTS: Among the case group, 89% had a TT TaqI genotype, whereas 57% of control had this genotype (odds ratio [OR] = 5.16, 95% confidence interval [CI] = 1.46-18.22). A similar pattern was seen for the FokI genotype, although this was not statistically significant (OR = 2.33, 95% CI = 0.86-6.29). The frequency of the HER-2 Ile/Ile genotype was higher in cases (79%) compared to control subjects (66%), although this was not statistically significant (OR = 1.94, 95% CI = 0.67-5.63). CONCLUSION: This study shows that the VDR TaqI polymorphism is associated with a group of men with BPH who are at an increase risk of PRCa, providing a potential tool to assist prediction strategies for this important disease.
Original languageEnglish
Pages (from-to)447-451
Number of pages5
JournalSaudi Medical Journal
Volume25
Issue number4
Publication statusPublished - 1 Apr 2004

Fingerprint

Calcitriol Receptors
Hyperplasia
Prostate
Prostatic Neoplasms
Prostatic Hyperplasia
Genotype
Odds Ratio
Confidence Intervals
Restriction Fragment Length Polymorphisms
Genes
Cell Differentiation
Cause of Death
Cell Proliferation

Keywords

  • Case-Control Studies
  • Genes, erbB-2
  • Genetic Predisposition to Disease
  • Humans
  • Male
  • Polymorphism, Genetic
  • Prostatic Hyperplasia
  • Prostatic Neoplasms
  • Receptors, Calcitriol
  • Risk Factors
  • prostate-cancer
  • tropical-medicine
  • prostate
  • human
  • risk-factor
  • polymorphism
  • vitamin D
  • hyperplasia

Cite this

Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. / Tayeb, Mohammed T; Clark, Caroline; Haites, Neva Elizabeth; Sharp, Linda; Murray, Graeme Ian; McLeod, Howeard L.

In: Saudi Medical Journal, Vol. 25, No. 4, 01.04.2004, p. 447-451.

Research output: Contribution to journalArticle

Tayeb, MT, Clark, C, Haites, NE, Sharp, L, Murray, GI & McLeod, HL 2004, 'Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia', Saudi Medical Journal, vol. 25, no. 4, pp. 447-451.
Tayeb, Mohammed T ; Clark, Caroline ; Haites, Neva Elizabeth ; Sharp, Linda ; Murray, Graeme Ian ; McLeod, Howeard L. / Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. In: Saudi Medical Journal. 2004 ; Vol. 25, No. 4. pp. 447-451.
@article{af485ff3d23748b08806e3b0239e9594,
title = "Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia",
abstract = "OBJECTIVE: Prostate cancer (PRCa) is one of the most common causes of cancer death in men and determinants of PRCa risk remain largely unidentified. Benign prostatic hyperplasia (BPH) is found in the majority of ageing men and has been associated with PRCa. Many candidate genes have been suggested to be involved in PRCa, such as those that are central to cellular growth and differentiation in the prostate gland. The vitamin D receptor (VDR) and HER-2 protooncogene have been shown to be involved in the regulation of cell proliferation and differentiation in prostate cells. Genetic variations of these genes could be useful to detect BPH patients that have a higher risk of developing PRCa. This study used a case-control design to assess the predictive value of 3 polymorphisms in VDR (TaqI and FokI) and HER-2 (Val655Ile) to determine the risk of developing PRCa in patients with BPH. METHODS: Polymorphisms were detected by RFLP analysis. The study evaluated 28 patients who presented with PRCa at least 6 years after the diagnosis of BPH and 56 matched patients with BPH who did not progress to PRCa over a comparable period. The study was carried out in University of Aberdeen, Foresterhill, Aberdeen, United Kingdom in the year 2002. RESULTS: Among the case group, 89{\%} had a TT TaqI genotype, whereas 57{\%} of control had this genotype (odds ratio [OR] = 5.16, 95{\%} confidence interval [CI] = 1.46-18.22). A similar pattern was seen for the FokI genotype, although this was not statistically significant (OR = 2.33, 95{\%} CI = 0.86-6.29). The frequency of the HER-2 Ile/Ile genotype was higher in cases (79{\%}) compared to control subjects (66{\%}), although this was not statistically significant (OR = 1.94, 95{\%} CI = 0.67-5.63). CONCLUSION: This study shows that the VDR TaqI polymorphism is associated with a group of men with BPH who are at an increase risk of PRCa, providing a potential tool to assist prediction strategies for this important disease.",
keywords = "Case-Control Studies, Genes, erbB-2, Genetic Predisposition to Disease, Humans, Male, Polymorphism, Genetic, Prostatic Hyperplasia, Prostatic Neoplasms, Receptors, Calcitriol, Risk Factors, prostate-cancer, tropical-medicine, prostate , human, risk-factor, polymorphism, vitamin D, hyperplasia",
author = "Tayeb, {Mohammed T} and Caroline Clark and Haites, {Neva Elizabeth} and Linda Sharp and Murray, {Graeme Ian} and McLeod, {Howeard L.}",
year = "2004",
month = "4",
day = "1",
language = "English",
volume = "25",
pages = "447--451",
journal = "Saudi Medical Journal",
issn = "0379-5284",
publisher = "Saudi Arabian Armed Forces Hospital",
number = "4",

}

TY - JOUR

T1 - Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia

AU - Tayeb, Mohammed T

AU - Clark, Caroline

AU - Haites, Neva Elizabeth

AU - Sharp, Linda

AU - Murray, Graeme Ian

AU - McLeod, Howeard L.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - OBJECTIVE: Prostate cancer (PRCa) is one of the most common causes of cancer death in men and determinants of PRCa risk remain largely unidentified. Benign prostatic hyperplasia (BPH) is found in the majority of ageing men and has been associated with PRCa. Many candidate genes have been suggested to be involved in PRCa, such as those that are central to cellular growth and differentiation in the prostate gland. The vitamin D receptor (VDR) and HER-2 protooncogene have been shown to be involved in the regulation of cell proliferation and differentiation in prostate cells. Genetic variations of these genes could be useful to detect BPH patients that have a higher risk of developing PRCa. This study used a case-control design to assess the predictive value of 3 polymorphisms in VDR (TaqI and FokI) and HER-2 (Val655Ile) to determine the risk of developing PRCa in patients with BPH. METHODS: Polymorphisms were detected by RFLP analysis. The study evaluated 28 patients who presented with PRCa at least 6 years after the diagnosis of BPH and 56 matched patients with BPH who did not progress to PRCa over a comparable period. The study was carried out in University of Aberdeen, Foresterhill, Aberdeen, United Kingdom in the year 2002. RESULTS: Among the case group, 89% had a TT TaqI genotype, whereas 57% of control had this genotype (odds ratio [OR] = 5.16, 95% confidence interval [CI] = 1.46-18.22). A similar pattern was seen for the FokI genotype, although this was not statistically significant (OR = 2.33, 95% CI = 0.86-6.29). The frequency of the HER-2 Ile/Ile genotype was higher in cases (79%) compared to control subjects (66%), although this was not statistically significant (OR = 1.94, 95% CI = 0.67-5.63). CONCLUSION: This study shows that the VDR TaqI polymorphism is associated with a group of men with BPH who are at an increase risk of PRCa, providing a potential tool to assist prediction strategies for this important disease.

AB - OBJECTIVE: Prostate cancer (PRCa) is one of the most common causes of cancer death in men and determinants of PRCa risk remain largely unidentified. Benign prostatic hyperplasia (BPH) is found in the majority of ageing men and has been associated with PRCa. Many candidate genes have been suggested to be involved in PRCa, such as those that are central to cellular growth and differentiation in the prostate gland. The vitamin D receptor (VDR) and HER-2 protooncogene have been shown to be involved in the regulation of cell proliferation and differentiation in prostate cells. Genetic variations of these genes could be useful to detect BPH patients that have a higher risk of developing PRCa. This study used a case-control design to assess the predictive value of 3 polymorphisms in VDR (TaqI and FokI) and HER-2 (Val655Ile) to determine the risk of developing PRCa in patients with BPH. METHODS: Polymorphisms were detected by RFLP analysis. The study evaluated 28 patients who presented with PRCa at least 6 years after the diagnosis of BPH and 56 matched patients with BPH who did not progress to PRCa over a comparable period. The study was carried out in University of Aberdeen, Foresterhill, Aberdeen, United Kingdom in the year 2002. RESULTS: Among the case group, 89% had a TT TaqI genotype, whereas 57% of control had this genotype (odds ratio [OR] = 5.16, 95% confidence interval [CI] = 1.46-18.22). A similar pattern was seen for the FokI genotype, although this was not statistically significant (OR = 2.33, 95% CI = 0.86-6.29). The frequency of the HER-2 Ile/Ile genotype was higher in cases (79%) compared to control subjects (66%), although this was not statistically significant (OR = 1.94, 95% CI = 0.67-5.63). CONCLUSION: This study shows that the VDR TaqI polymorphism is associated with a group of men with BPH who are at an increase risk of PRCa, providing a potential tool to assist prediction strategies for this important disease.

KW - Case-Control Studies

KW - Genes, erbB-2

KW - Genetic Predisposition to Disease

KW - Humans

KW - Male

KW - Polymorphism, Genetic

KW - Prostatic Hyperplasia

KW - Prostatic Neoplasms

KW - Receptors, Calcitriol

KW - Risk Factors

KW - prostate-cancer

KW - tropical-medicine

KW - prostate

KW - human

KW - risk-factor

KW - polymorphism

KW - vitamin D

KW - hyperplasia

M3 - Article

VL - 25

SP - 447

EP - 451

JO - Saudi Medical Journal

JF - Saudi Medical Journal

SN - 0379-5284

IS - 4

ER -